UBS Group Analysts Give Novartis (NOVN) a CHF 83 Price Target

UBS Group set a CHF 83 target price on Novartis (VTX:NOVN) in a report issued on Friday morning, Borsen Zeitung reports. The brokerage currently has a neutral rating on the stock.

NOVN has been the topic of a number of other research reports. Barclays set a CHF 75 price objective on Novartis and gave the stock a sell rating in a report on Friday, February 1st. Credit Suisse Group set a CHF 84 price objective on Novartis and gave the stock a neutral rating in a report on Friday, April 5th. Jefferies Financial Group set a CHF 95 price objective on Novartis and gave the stock a buy rating in a report on Wednesday, April 17th. Kepler Capital Markets set a CHF 87 price objective on Novartis and gave the stock a buy rating in a report on Tuesday, May 21st. Finally, Goldman Sachs Group set a CHF 98 price objective on Novartis and gave the stock a buy rating in a report on Wednesday, April 24th. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and eight have assigned a buy rating to the company. Novartis has an average rating of Hold and an average target price of CHF 88.41.

Novartis has a 1 year low of CHF 72.45 and a 1 year high of CHF 88.30.

About Novartis

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

Recommended Story: Is a Roth IRA right for you?

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.